2-Trifluoromethyl-2'-methoxychalcone
目录号 : GC15355A potent activator of Nrf2
Cas No.:1309371-03-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
2-Trifluoromethyl-2'-methoxychalcone is a Nrf2 activator.
Nrf2-mediated activation of antioxidant response element is a key process of molecular mechanisms regulating the protective function of phase II detoxification and antioxidant enzymes against oxidative stress, carcinogenesis, and inflammation.
In vitro: The expression of luciferase gene under the control of NQO1-ARE sequence was measured using stably transfected Beas-2B cells treated with 2-trifluoromethyl-2'-methoxychalcone. Results showed that the exposure to 2-trifluoromethyl-2'-methoxychalcone led to a significant concentration-dependent increase in luciferase activity. Moreover, Beas-2B cells were coincubated with 2-trifluoromethyl-2'-methoxychalcone and with or without N-acetylcysteine, and it was found that 2-trifluoromethyl-2'-methoxychalcone could potentially increase the expression of Nr2-regulated antioxidant genes in the presence of N-acetylcysteine [1].
In vivo: C57BL/6 mice were treated with a single dose of vehicle or 2-trifluoromethyl-2'-methoxychalcone or sulforaphane as the positive control, and small intestines were harvested 24 h later. Results showed that the expression of GCLM and NQO1 in the small intestine of mice treated with 2-trifluoromethyl-2'-methoxychalcone was 6-fold and 10-fold higher compared to vehicle, respectively. In addition, the expression of GCLM and NQO1 in the small intestine treated with 2-trifluoromethyl-2'-methoxychalcone was 3-fold and 5-fold higher compared to sulforaphane, respectively [1].
Clinical trial: Up to now, 2-trifluoromethyl-2'-methoxychalcone is still in the preclinical development stage.
Reference:
[1] V. Kumar, S. Kumar, M. Hassan, et al. Novel chalcone derivatives as potent Nrf2 activators in mice and human lung epithelial cells. Journal of Medicinal Chemistry 54(12), 4147-4159 (2011).
| Cas No. | 1309371-03-6 | SDF | |
| 化学名 | 1-(2-methoxyphenyl)-3-[2-(trifluoromethyl)phenyl]-2E-propen-1-one | ||
| Canonical SMILES | COC1=C(C(/C=C/C2=CC=CC=C2C(F)(F)F)=O)C=CC=C1 | ||
| 分子式 | C17H13F3O2 | 分子量 | 306.3 |
| 溶解度 | ≤11mg/ml in ethanol;5mg/ml in DMSO;14mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2648 mL | 16.3239 mL | 32.6477 mL |
| 5 mM | 0.653 mL | 3.2648 mL | 6.5295 mL |
| 10 mM | 0.3265 mL | 1.6324 mL | 3.2648 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。